Comments

ArriVent BioPharma

AVBPNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$21.14
0.633.07%
At Close: -
$21.14
00.00%
After Hours: 4:01 PM EDT
15 minutes delayed
ArriVent BioPharma (AVBP) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$35.00
Lowest Price Target1
$25.00
Consensus Price Target1
$29.25

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

ArriVent BioPharma (NASDAQ:AVBP) Stock, Analyst Ratings, Price Targets, Forecasts

ArriVent BioPharma Inc has a consensus price target of $29.25 based on the ratings of 4 analysts. The high is $35 issued by Jefferies on February 20, 2024. The low is $25 issued by HC Wainwright & Co. on June 6, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 6, 2024, May 9, 2024, and April 30, 2024, respectively. With an average price target of $25 between HC Wainwright & Co., there's an implied 18.26% upside for ArriVent BioPharma Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Citigroup
Jefferies
Goldman Sachs

1calculated from analyst ratings

Analyst Ratings for ArriVent BioPharma

Buy NowGet Alert
06/06/2024Buy Now18.26%HC Wainwright & Co.
Robert Burns
$25 → $25ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now18.26%HC Wainwright & Co.
Robert Burns
 → $25ReiteratesBuy → BuyGet Alert
04/30/2024Buy Now18.26%HC Wainwright & Co.
Robert Burns
 → $25Initiates → BuyGet Alert
02/20/2024Buy Now41.91%Citigroup
Yigal Nochomovitz
 → $30Initiates → BuyGet Alert
02/20/2024Buy Now65.56%Jefferies
Kelly Shi
 → $35Initiates → BuyGet Alert
02/20/2024Buy Now27.72%Goldman Sachs
Corinne Johnson
 → $27Initiates → BuyGet Alert

FAQ

Q

What is the target price for ArriVent BioPharma (AVBP) stock?

A

The latest price target for ArriVent BioPharma (NASDAQ:AVBP) was reported by HC Wainwright & Co. on June 6, 2024. The analyst firm set a price target for $25.00 expecting AVBP to rise to within 12 months (a possible 18.26% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ArriVent BioPharma (AVBP)?

A

The latest analyst rating for ArriVent BioPharma (NASDAQ:AVBP) was provided by HC Wainwright & Co., and ArriVent BioPharma reiterated their buy rating.

Q

When was the last upgrade for ArriVent BioPharma (AVBP)?

A

There is no last upgrade for ArriVent BioPharma

Q

When was the last downgrade for ArriVent BioPharma (AVBP)?

A

There is no last downgrade for ArriVent BioPharma.

Q

When is the next analyst rating going to be posted or updated for ArriVent BioPharma (AVBP)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ArriVent BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ArriVent BioPharma was filed on June 6, 2024 so you should expect the next rating to be made available sometime around June 6, 2025.

Q

Is the Analyst Rating ArriVent BioPharma (AVBP) correct?

A

While ratings are subjective and will change, the latest ArriVent BioPharma (AVBP) rating was a reiterated with a price target of $25.00 to $25.00. The current price ArriVent BioPharma (AVBP) is trading at is $21.14, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch